ISSN 1933-0863 (PRINT) ISSN 1933-0871 (ONLINE)
Introduction
The 2025 International Kidney Cancer Symposium—North America (IKCS-NA), held November 12–15 in Denver, showcased one of the most diverse and scientifically rich programs in recent years. With several multidisciplinary sessions, the meeting highlighted key developments across preclinical discovery, clinical trials, patient-centered care, regulatory navigation, and novel therapeutics. Notably, there was an increased emphasis on non–clear cell RCC, biomarker-guided therapy, AI-enabled pathology, and integration of cellular immunotherapies, reflecting the accelerating complexity of kidney cancer research and clinical management.
This summary will focus on key findings and discussions from the oral presentations, alongside highlights from selected poster presentations, which offer novel insights into translational science, clinical trials, and therapeutic optimization in renal cell carcinoma (RCC).
- Preclinical Science: Nanotechnology, Immune Interactions, and Metabolic Vulnerabilities
The opening preclinical sessions established the next frontier in RCC treatment: engineering more precise and potent immune responses.
1.1 Nanoparticle-based immunotherapeutics
In the opening preclinical session, Andrew Wang, MD, discussed the design of multifunctional nanoparticles capable of co-delivering immunostimulatory payloads and enhancing antigen presentation in RCC. His group’s preclinical systems integrated STING agonists and tumor-targeted delivery, achieving improved tumor regression in murine models. Nanoparticle-enabled immunotherapy is emerging as a platform capable of overcoming the poor innate immune activation characteristic of RCC tumors.
1.2 Neoantigen vaccine therapy
David Braun, MD, PhD, highlighted advances in neoantigen discovery pipelines, emphasizing RNA-based prediction models, single-cell sequencing, and personalized vaccine constructs. Preclinical data suggest that vaccination may synergize with anti-PD-1 therapy, strengthening T-cell diversity and increasing infiltration of tumor-specific CD8+ clones.
1.3 Tumor-immune microenvironment (TIME) as therapeutic guide
Abhishek Chakraborty, PhD, and Sangeeta Goswami, MD, PhD, both underscored the complexity of RCC’s immune landscape, noting that interactions among myeloid cells, tumor fibroblasts, and exhausted T-cell populations may drive immunotherapy resistance. A recurring theme across IKCS 2025 was the central role of myeloid suppression and the need for strategies that remodel the TIME.
1.4 The STING pathway and SPOP inhibition
Pengda Liu, PhD, presented compelling evidence that SPOP inhibition stabilizes STING, promoting type-I interferon signaling and increasing responsiveness to immune checkpoint inhibitors. These findings tie metabolic stress and ubiquitin-mediated regulation directly to immunotherapy efficacy.
1.5 Emerging insights in non–clear cell biology
Lisa Henske, MD, James Brugarolas, MD, PhD, and Pavlos Msaouel, MD, PhD, presented cutting-edge updates in chromophobe RCC, translocation RCC, and renal medullary carcinoma (RMC). A highlight was the discussion of metabolic reprogramming in Birt–Hogg–Dubé syndrome delivered by Mehdi Mollapour, PhD, demonstrating how oxidative phosphorylation–targeted therapies and HIF-pathway modulation may generate actionable vulnerabilities.
- Clinical Challenges: Oligometastatic Disease, Imaging Innovation, and Adjuvant-Era Decisions
The conference addressed the increasingly complex decisions faced in localized, locally advanced, and oligometastatic disease
2.1 PET imaging and surgical boundaries
Aradhana Venkatesan, MD, presented a comprehensive overview of current PET tracers in RCC. While FDG remains variably reliable in primary lesions, emerging tracers—including CAIX-targeted PET and PSMA-PET analogues—show growing utility in defining metastases and informing metastasis-directed therapy.
Jason Abel, MD, FACS, explored the limits of surgical resectability in locally advanced RCC, incorporating tumor thrombus assessment, vena cava involvement, and the evolving question of neoadjuvant immunotherapy as a debulking strategy.
2.2 Adjuvant therapy and frontline systemic sequencing
Andy Hahn, MD, addressed the increasingly complex landscape shaped by KEYNOTE-564 and emerging adjuvant trials. The question of whether adjuvant pembrolizumab alters the biology of later metastatic recurrence remains open; early real-world observations presented at IKCS suggest altered response patterns in subsequent therapy lines.
Ben Garmezy, MD, provided an excellent overview of ongoing oligometastatic trials testing combinations of SBRT, IO therapies, and anti-angiogenic agents, reflecting a strong shift toward curative-intent or durable-control strategies for select patients.
3. Navigating Clinical Trials and Regulatory Barriers
3.1 Trial activation efficiency and AI-enabled processes
Manoj Bupathi, MD, PhD, and Irbaz Riaz, MD, PhD, discussed bottlenecks in trial activation, including contracting delays, regulatory redundancy, and site-activation variance. Early pilots of AI systems for protocol parsing and IRB query prediction have reduced activation time by 20–30% in select centers.
3.2 Building trial networks & balanced portfolios
Eric Jonasch, MD, emphasized the necessity of robust multi-institution research networks, especially for rare tumor subtypes. Sumanta Pal, MD, FASCO, recommended trial portfolios that integrate phase I exploratory biology, phase II signal-seeking approaches, and registration-directed trials, preventing over-concentration in any single strategy.
Ulka Vaishampayan, MBBS, provided insights into FDA-pharma navigation, highlighting the evolving expectations around companion diagnostics, response endpoints, and minimal residual disease (MRD) markers.
4. Patient-Centered Care: Survivorship Burden, Cognitive Impact, and Nutrition
The 2025 patient-centric session reflected the growing recognition that long-term survivorship introduces unique burdens.
4.1 Treatment burden and cognitive effects
David Sheppard, PhD, presented evidence linking multitargeted TKI therapy and IO-TKI regimens to cognitive strain, fatigue, and decision-making impairment. Structured, multidisciplinary survivorship programs—incorporating cognitive rehabilitation and symptom-tracking apps—were proposed as actionable pathways.
4.2 Nutrition and lifestyle
Michael Staehler, MD, PhD, reviewed recent studies showing associations between plant-forward dietary patterns, reduced systemic inflammation, and slower progression in metastatic RCC cohorts. Although causality remains unproven, nutrition counseling is gaining traction as a modifiable adjunct to therapy.
4.3 Managing difficult toxicities
Dan Geynisman, MD, outlined strategies for managing hard-to-treat adverse events such as refractory diarrhea, chronic hand–foot syndrome, and hypertension, emphasizing early dose modification rather than reactive management.
5. AYA Kidney Tumors: VHL Management & Late Effects
Candace Granberg, MD, Nicholas Cost, MD, and colleagues highlighted several critical considerations in the AYA population. These included the increased prevalence of hereditary syndromes such as VHL, the need to address fertility and endocrine health proactively, and the long-term toxicities of systemic and local therapies that may affect patients well into adulthood. Michael Ortiz, MD, highlighted that although Wilms tumors in AYAs are rare, treatment paradigms increasingly borrow from pediatric cooperative group protocols, resulting in improved survival.
6. Oral Abstract Session Highlights
The Friday afternoon abstract session delivered high-impact data across several domains, introducing novel agents and critical clinical context.
6.1 Cabozantinib for RCC brain metastases (CABRAMET Trial)
Sylvie Negrier, MD, PhD, presented encouraging intracranial responses for Cabozantinib in patients with non-locally pretreated brain metastases, reinforcing its CNS penetration and expanding therapeutic options.
6.2 Environmental exposure: Wildfire-driven PM2.5 and RCC survival
Shuchi Gulati, MD, MSc, presented data showing that exposure to wildfire-associated PM2.5 correlated with decreased survival in a California-based RCC cohort, raising critical questions about environmental factors and tumor aggressiveness. This is one of the first large datasets linking environmental toxins and RCC outcomes.
6.3 AI-driven multiplex immunofluorescence for predicting IO response
Yuanquan Yang, MD, PhD, showed that AI-assisted analysis of multiplex IF identified specific T-cell/myeloid spatial signatures predictive of immunotherapy response, validating emerging spatial-biology biomarkers.
6.4 Enhancing the abscopal effect with strategic trimodal therapy
Krishnendu Pal, PhD presented that combinatorial therapy involving radiation, targeted therapy, and immune activation amplified the abscopal response in RCC models. This offers a mechanistic rationale for several ongoing trials exploring SBRT + IO + VEGF inhibition.
6.5 Chromophobe RCC with sarcomatoid features: Multi-institution outcomes
Sahil Doshi, MD, presented a multi-institution analysis showing exceptionally poor outcomes for sarcomatoid variants of metastatic chromophobe RCC.
6.6 FH-deficient RCC: Cabozantinib + nivolumab outcomes
Maria Carlo, MD, reported clinically meaningful responses to Cabozantinib plus Nivolumab in fumarate-hydratase–deficient RCC.
6.7 Combinations of anti-angiogenic agents and ICIs in ccRCC metastases
Stefan Maksimovic, MD presented that updated multicenter data reaffirmed the durability of IO-TKI combinations and suggested TKI choice may influence organ-specific response patterns.
6.8 XmAb819 (ENPP3 × CD3 bispecific antibody): First-in-human results
Perhaps the most anticipated abstract, Monty Pal, MD, FASCO, presented early safety and antitumor activity of XmAb819 —a bispecific targeting ENPP3 on RCC cells and CD3 on T cells. Preliminary data showed robust immune activation, manageable cytokine-release profiles, and preliminary tumor shrinkage in heavily pretreated ccRCC.
7. Novel Trial Designs, Cellular Therapies, and Ongoing Investigations
7.1 Trial design innovation
Ruitao Lin, PhD, presented updated statistical frameworks for adaptive trial design, including Bayesian models that may reduce sample sizes while increasing power. Daniel Shapiro, MD, encouraged more nuanced interpretation of recently published trials, noting that time-to-event endpoints must be contextualized within biological heterogeneity.
7.2 Cellular therapies in RCC
While still early, Pavlos Msaouel, MD, PhD, and others highlighted ongoing efforts in CAR-T, TRuC T cells, and NK-cell engineering. Emerging translational data suggest that targeting CD70, CAIX, and enriched metabolic antigens may generate more durable responses.
8. Biomarker-Driven Therapy: Liquid Biopsy, KIM-1, and Gene Expression Signatures
8.1 Liquid biopsy
Arnab Basu, MBBS, MPH, reviewed circulating tumor DNA (ctDNA) kinetics as a potential early indicator of treatment failure. Several studies now show that rising ctDNA precedes radiographic progression by 6–12 weeks.
8.2 KIM-1
Wenxin (Vincent) Xu, MD, discussed KIM-1 as a highly promising biomarker—particularly for early detection and nephrotoxicity monitoring. Although not yet standard in clinical practice, assay standardization is underway.
8.3 RNA-seq–based signatures
Scott Haake, MD, PhD, presented next-generation ccRCC gene-expression signatures capable of distinguishing angiogenic, T-effector-predominant, and myeloid-inflamed phenotypes, offering a future where treatment selection could be mechanistically guided.
9. Later-Line Therapy Selection: 2nd–4th Line Strategies
Arpita Desai, MD, and Lisa Henske, MD, discussed strategic sequencing of targeted therapies and IO rechallenge. Martin Voss, MD, emphasized that non–clear cell RCC remains under-represented, urging incorporation of histology-specific biology into trial designs.
Anand Swaminath, MD, addressed the increasingly relevant question of oligoprogression, advocating for metastasis-directed therapy (MDT) in selected cases to prolong the lifespan of systemic therapy lines.
10. Special Sessions and Awards
The Christopher G. Wood Rising Star Award was awarded to Abhishek A. Chakraborty, whose lecture focused on mechanistic immunobiology and future drug-target discovery.
The Nicholas J. Vogelzang Humanitarian Award was presented to Michael A. S. Jewett, MD, recognizing decades of leadership in RCC surgery and survivorship advocacy.
Andrew C. Novick Award was awarded to E. Jason Abel, MD, FACS, for excellence in surgical innovation and multidisciplinary care integration.
11. Poster Spotlights
The poster sessions covered a wide scientific landscape. Particularly notable were innovations in spatial biology and AI-powered tissue analytics, studies addressing racial and socioeconomic disparities in RCC, real-world effectiveness data for IO–TKI therapies, toxicity trends among older adults, and exploratory work using metabolic imaging to detect early treatment response.
Conclusion
IKCS 2025 delivered a rich and diverse program that will shape clinical practice and research for years to come. From advances in nanoparticle-based immunomodulation to the emergence of bispecific antibodies, adaptive trial designs, and survivorship-focused strategies, the symposium highlighted the rapidly evolving landscape of kidney cancer care. The sustained emphasis on patient-centered approaches and the management of hard-to-treat adverse events underscored the importance of improving not only survival but also quality of life. Equally impactful were discussions on patient experience, environmental influences on disease outcomes, regulatory and trial-activation efficiencies, and the distinct needs of AYA patients. Together, these themes reinforced that meaningful progress in RCC requires not just better therapies, but better care systems.
As we move toward 2026, the field stands at a pivotal intersection of biology, technology, and multidisciplinary collaboration. IKCS 2025 offered a compelling preview of the innovations and directions that may define the next decade of kidney cancer research.